Scinai Immunotherapeutics (SCNI) Assets Average (2020 - 2026)

Scinai Immunotherapeutics has disclosed Assets Average across 7 years of filings, most recently posting $17.4 million for Q2 2026.

• In Q2 2026, Assets Average changed N/A year-over-year to $17.4 million; the TTM figure through Jun 2026 stood at $17.4 million (changed N/A YoY), while the FY2025 annual figure was $12.5 million, down 18.91% from the prior year.
• Assets Average came in at $17.4 million for Q2 2026 at Scinai Immunotherapeutics, up from $14.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $25.2 million in Q1 2023 to a low of $11.7 million in Q4 2025.
• Average Assets Average over 5 years is $18.0 million, with a median of $17.4 million recorded in 2026.
• Year-over-year, Assets Average plunged 31.45% in 2024 and dropped 8.72% in 2025.
• Over 5 years, Assets Average stood at $24.1 million in 2022, then fell by 25.13% to $18.0 million in 2023, then slipped by 28.69% to $12.9 million in 2024, then retreated by 8.72% to $11.7 million in 2025, then surged by 48.14% to $17.4 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $17.4 million in Q2 2026, $14.6 million in Q1 2026, and $11.7 million in Q4 2025.